Audit of antipsychotic prescribing in a private psychiatric hospital

REFERENCES

• Ghaemi SN, Sachs GS. Long‐term risperidone treatment in bipolar disorder: 6‐month follow up. International Clinical Psychopharmacology 1997; 12: 333–338
   PubMed Web of Science ®Google Scholar
• Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. Journal of Clinical Psychiatry 2000; 61(Suppl. 14)33–42
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Cherry EL, Katzow A, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disorders 2000; 2: 196–199
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and the risk of tardive dyskinesia. Journal of Clinical Psychiatry 2000; 61(Suppl. 4)33–38
   PubMed Web of Science ®Google Scholar
• Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia (Cochrane Review). The Cochrane Library. Issue 2. Update Software, Oxford 2003
   Google Scholar
• Solomons K, Geiger O. Olanzapine use in the elderly: a retrospective analysis. Canadian Journal of Psychiatry 2000; 45: 151–155
   PubMed Web of Science ®Google Scholar
• Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive‐compulsive and related disorders. Journal of Clinical Psychiatry 1997; 58: 119–122
   PubMed Web of Science ®Google Scholar
• Schweitzer I. Does risperidone have a place in the treatment of nonschizophrenic patients?. International Clinical Psychopharmacology 2001; 16: 1–19
   PubMed Web of Science ®Google Scholar
• Grubber AJ, Cole JO. Antidepressant effects of flupenthixol. Pharmacotherapy 1991; 11: 450–459
   PubMedGoogle Scholar
• Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. Journal of Affective Disorders 1982; 4: 173–193
   PubMed Web of Science ®Google Scholar
• Casey DE. The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 1997; 58(Suppl. 10)55–62
   PubMed Web of Science ®Google Scholar
• Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry 1997; 170: 422–425
   PubMed Web of Science ®Google Scholar
• Keks N, Mazumdar P, Steele K. The new antipsychotics: how much better are they?. Australian Family Physician 2000; 29: 445–450
   PubMedGoogle Scholar
• The American Psychiatric Press Textbook of Psychopharmacology2nd edn., AF Schatzberg, CB Nemeroff. American Psychiatric Press, Washington, DC 1998
   Google Scholar
• Parker G. Augmentation with atypical antipsychotics. Psychiatric Times 2002; 19, http://www.psychiatrictimes.com/p021069.html
   Google Scholar
• Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47‐week study. American Journal of Psychiatry 2003; 160: 1263–1271
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2001; 15: 131–134
   Google Scholar
• Pridmore S, Samilowitz H, Oberoi G. Will the atypical antipsychotics be analgesics?. Australasian Psychiatry 2003; 11: 59–61
   Google Scholar
• Stahl SM. Psychopharmacology of Antipsychotics. Martin Dunitz, London 1999
   Google Scholar
• Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Review of Contemporary Pharmacotherapy 1995; 6: 197–208
   Google Scholar
• Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical anti‐psychotics: new indications and new populations. Journal of Psychiatric Research 2001; 35: 187–191
   PubMed Web of Science ®Google Scholar
• Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australasian Psychiatry 2000; 8: 220–225
   Google Scholar
• Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33: 896–901
   PubMed Web of Science ®Google Scholar
• Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australian States and Territories between July 1995 and December 2001. Australasian Psychiatry 2003; 11: 267–272
   Google Scholar
• Goldney RD. A comparison of private and public psychiatry in three hospitals. Aus‐ tralasian Psychiatry 1999; 7: 20–22
   Google Scholar
• Ellis PM, Hickie IB, Smith DAR. for the RANZCP Clinical Practice Guideline Team for Depression. Summary of guideline for the treatment of depression. Australasian Psychiatry 2003; 11: 34–38
   Google Scholar
• Bowden CL. Acute and maintenance treatment with mood stabilizers. International Journal of Neuropsychopharmacology 2003; 6: 269–275
   PubMed Web of Science ®Google Scholar
• Kaplan and Sadock's Comprehensive Textbook of Psychiatry7th edn., B Sadock, V Sadock. Lippincott Williams & Wilkins, Philadelphia 2000
   Google Scholar
• Commonwealth of Australia Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Commonwealth Department of Health and Ageing, Canberra 2002
   Google Scholar
• MediMedia MIMS Australia. 2002 MIMS Annual26th edn. Tien Wah Press, Singapore 2002
   Google Scholar